Skip to content
NBlaz – Lifestyle
Author:
SHY Therapeutics
SHY Therapeutics Announces the First Patient Has Been Dosed in Phase 1 Clinical Trial Evaluating SHY-ONC6, a Novel, Oral Proteasome Inhibitor for the Treatment of Solid Tumors
August 4, 2026